source
- Novartis halts Phase 2 lupus nephritis trial of Fabhalta, cites strategic reasonsNovartis has stopped a Phase 2 study of its complement blocker Fabhalta (iptacopan) in patients with lupus nephritis, a kidney involving form of the disease. The company said the decision was base…
- Sino Biological offers validated cytokines to improve organoid culture and researchOrganoids are three-dimensional cell models that mimic key features of real tissues, and they rely on specific signaling molecules to grow and differentiate. Key cytokines such as R-spondin 1, EGF…